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Abstract Cell surface receptors bind ligands expressed
on other cells (in trans) in order to communicate with
neighboring cells. However, an increasing number of cell
surface receptors are found to also interact with ligands
expressed on the same cell (in cis). These observations
raise questions regarding the biological role of such cis
interactions. Specifically, it is important to know whether
cis and trans binding have distinct functional effects and,
if so, how a single cell discriminates between interactions
in cis versus trans. Further, what are the structural fea-
tures that allow certain cell surface receptors to engage
ligand both on the same as well as on an apposed cell
membrane? Here, we summarize known examples of
receptors that display cis–trans binding and discuss the
emerging diversity of biological roles played by these
unconventional two-way interactions, along with their
structural basis.
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Abbreviations
BCR B cell receptor
BTLA B and T lymphocyte attenuator
HVEM Herpesvirus entry mediator
Ig Immunoglobulin
LILRB Leukocyte immunoglobulin-like receptor B
MHC-I Major histocompatibility complex class I
PIR-B Paired immunoglobulin-like receptor-B
Siglec Sialic acid-binding immunoglobulin-like lectin
Introduction
One of the first cell surface receptors shown to bind ligand
present in the plane of the same cell membrane was CD22,
a sialic acid-binding immunoglobulin-like lectin (Siglec)
expressed by B cells. Most CD22 was found to be
‘‘masked’’ by binding sialic acids attached to galactose (Sia
a2–6Gal) on N-linked glycans of glycoproteins expressed
on the B cell itself [1]. Sialidase treatment of B cells was
sufficient to unmask CD22 and allow binding of exogenous
sialoside probes. The preferential binding in cis is
explained by the high concentration of sialic acid on the B
cell surface (25–30 mM), which is around 100-fold higher
than the Kd of CD22 for sialic acid (0.1–0.3 mM) [2].
Indeed, CD22 binding of higher-affinity multivalent
sialoside probes does not require prior unmasking, and
trans ligand can compete with cis ligand for CD22 binding
in cell–cell conjugates [3]. These data suggest a dynamic
equilibrium, in which CD22 can switch between cis and
trans interactions, depending on the relative affinity/avidity
of the respective ligands. However, the nature of the rele-
vant sialic acid-modified cis ligand has remained elusive,
although CD22 is associated with the B cell receptor
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(BCR), CD45 and CD22 itself [4]. Functional conse-
quences of CD22 cis binding were proposed based on an
analysis of human B cell lines. Separation of CD22 from
the BCR in the B cell membrane by sequestration improved
B cell activation [5]. Similarly, B cells expressing a CD22
mutant that lacks sialic acid-binding function were hyper-
responsive to stimulation through the BCR [6]. Cis binding
is thus thought to set a signaling threshold, which prevents
overstimulation of B cells after BCR cross-linking by
antigen. This notion has been confirmed in several (but not
all) mouse models, in which CD22 or sialic acid modifi-
cations have been disrupted completely or partially (for
recent reviews, see [7, 8]). The work on Siglecs has pro-
vided a framework to investigate the role of cis–trans
interactions in other receptor–ligand systems.
Renewed interest in the fact that certain cell surface
receptors bind ligands expressed on the same membrane
has stemmed from the analysis of natural killer (NK) cell
receptors specific for major histocompatibility complex
class I (MHC-I) molecules [9]. Such receptors were orig-
inally identified based on their ability to inhibit the effector
function of NK cells in response to specific allelic variants
of MHC-I molecules expressed on target cells [10, 11].
Some of these NK receptors were subsequently found to
constitutively bind to the same MHC-I ligand expressed by
the NK cell itself. This represented one of the first
instances where cis–trans binding of a cell surface receptor
was based on protein–protein interactions and where the cis
and trans ligands were identical (for a review, see [12]).
Additional examples of receptors that can bind ligand in
both cis and trans have since been reported [13–17], sug-
gesting that such two-way interactions are more common
than initially thought. In addition, it has emerged that cis
interactions can serve distinct purposes and that there may
be multiple structural solutions to the problem of how a cell
surface receptor can engage the identical ligand on the
same as well as on an apposed cell. Here, we summarize
recent examples of receptor–ligand systems where evi-
dence for cis and trans binding has been obtained. We also
discuss the structural basis for this unconventional type of
interaction and compare the biological roles of cis binding
in these different systems. We reserve the term ‘‘cis
interaction’’ for receptors that can bind the identical ligand
expressed on the same and on an apposed cell, as sche-
matically shown in Fig. 1.
Biological roles of cis–trans interactions of cell surface
receptors
Cis association by inhibitory NK cell receptors specific
for MHC-I
One of the first cell surface receptors shown to bind ligand
in both cis and trans was the C-type lectin-like receptor
Ly49A [9], an inhibitory receptor specific for multiple
H-2D alleles expressed by NK cells [10]. Ly49A is the
founding member of a small receptor family, which allows
mouse NK cells to detect diseased host cells with non-
physiologically low levels of MHC-I molecules. Recogni-
tion of such cells is based on a dual receptor system
consisting of activating and MHC-I-specific inhibitory
receptors. Inhibitory receptors interrupt NK cell activation
signaling when a cell’s MHC-I levels are normal. When
MHC-I levels are low, inhibitory signaling does not occur,
which allows NK cell activation signaling to induce target
cell lysis. This recognition strategy is classically known as
‘‘missing-self recognition’’ [18].
In addition to binding H-2Dd expressed by potential
target cells (in trans), Ly49A is associated with H-2Dd
expressed on the NK cell itself (in cis) [9]. To inhibit NK
cell-mediated lysis, Ly49A binds H-2Dd on target cells
Fig. 1 Schematic representation of the structural basis for cis–trans
interaction by cell surface receptors. a Ly49 receptors reverse the
orientation of their ligand-binding domains relative to the NK cell
membrane using a long flexible stalk region. b LILRB1 has a shorter
stalk but is composed of four Ig domains, whereby MHC-I binding is
mediated by the two membrane-distal Ig domains. Cis binding, which
is likely based on a reversal of the orientation of the two distal Ig
domains, may be enabled by flexibility of the short hinge between Ig
domains 2 and 3. c Notch and Delta are rigid EGF repeat-containing
receptors. Symmetric binding sites allow anti-parallel (trans) and
parallel (cis) binding without a need for reversal of the ligand-binding
domains
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using a binding site beneath the peptide-binding platform
of H-2Dd [19–21]. This same binding site allows the
association of Ly49A with H-2Dd in cis [9]. Indeed, the
majority ([70%) of Ly49A molecules is bound in cis [22,
23] and only a minority remains available to bind ligand in
trans. Besides a high affinity for H-2Dd, Ly49A binds other
H-2D alleles with variable affinities [24]. Interestingly, the
affinity of Ly49A for a specific H-2D allele directly cor-
relates with the number of receptors bound in cis.
Consequently, the number of free receptors available to
bind MHC-I in trans decreases when the affinity of Ly49A
for ligand increases [25]. The association of Ly49A with
H-2Dd in cis is stable and, unlike Siglecs, there is no evi-
dence that cis-bound Ly49A can switch to trans ligand
during the formation of an immune synapse [22]. Finally, it
is important to point out that NK cells expressing a cis-
engaged Ly49 receptor are fully functional, which implies
that cis association does not result in constitutive inhibitory
signaling that renders NK cells non-functional. Collec-
tively, therefore, cis association of Ly49A with MHC-I
stably reduces the number of receptors that are available
for functional interaction with MHC-I on target cells [22].
The fact that the number of available receptors is reduced
when the affinity for H-2D is increased raises the possi-
bility that NK cell inhibition via Ly49A is relatively
independent of whether a given mouse strain expresses a
high or a low affinity H-2D allele. Notwithstanding, in a
given mouse strain, cis association lowers the threshold at
which NK cell activation exceeds inhibition during target
cell encounter [9]. Since cis association is stable, the
function of NK cells is constitutively improved. This does
not exclude the possibility that changes in the expression
levels of MHC-I or Ly49 on the surface of NK cells could
further modify the responsiveness of these effector cells.
Like Ly49A, most other inhibitory Ly49 receptors spe-
cific for MHC-I have the capacity to interact with MHC-I
molecules in cis [26, 27] (Table 1). Besides Ly49 family
receptors, NK cells use additional inhibitory receptors
specific for MHC-I. These include heterodimeric C-type
lectin-like CD94/NKG2 receptors, which are used by
human and rodent NK cells, as well as structurally unre-
lated killer immunoglobulin-like receptors (KIRs) and
leucocyte immunoglobulin-like receptor B1 (LILRB1)
(also termed LIR-1 or ILT2) expressed by human NK cells.
In contrast to Ly49 receptors, there is no evidence for cis
binding in the case of the mouse CD94/NKG2A receptor or
the human KIR family receptor KIR2DL1 (unpublished
data). However, cis association has been reported for
LILRB1 [28], which will be discussed below.
Certain receptors specific for MHC-I are not actually
expressed by NK cells and some activate rather than inhibit
cellular functions. For example, the MHC-I-specific Ly49Q
receptor improves the response of plasmacytoid dendritic
cells (pDC) to microbial infection. PDCs lacking Ly49Q
produce low amounts of type I interferon in response to
Toll-like receptor 9 (TLR9) stimulation by unmethylated
microbial cytosine guanine dinucleotide (CpG) DNA [29].
Similarly, the response is also low in mice devoid of
classical MHC-I molecules [29], suggesting that Ly49Q
improves the response of TLR9 in connection with MHC-I
binding. Indeed, Ly49Q co-localizes with MHC-I at the
cell surface [30] and most, but not all, Ly49Q is physically
associated with MHC-I in cis [27]. However, it is not
formally known whether cis binding of MHC-I by Ly49Q
Table 1 Cell surface receptors that interact with ligand expressed in trans and in cis

















Human Inh MHC-Ia/b Inh [14]
[28]
PIR-B Ig Mast, DC Mouse Inh MHC-Ia/b Inh [14], [35]
[16]
[16]




EphA4 Neuron Mouse Act Ephrin-A2 Comp. Inh. [13]
Plexin-A4 GAP, Ig Neuron Mouse Act Sema6a Comp. Inh. [17]




CTLL C-type lectin like, Ig immunoglobulin-like, TNFR tumor necrosis factor related, EGF epidermal growth factor related, GAP GTPase
activating protein domain, NK natural killer cells, pDC plasmacytoid dendritic cells, DC dendritic cell, Inh inhibitory, Act activating, Comp. inh.
competitive inhibition of trans binding, MHC-Ia classical major histocompatibility complex class I molecules, MHC-Ib non-classical MHC-I
molecules, BTLA B- and T-lymphocyte attenuator, HSV env herpes simplex virus envelope
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plays an essential role. Moreover, it is not clear how
Ly49Q improves the function of endosome-resident TLR9.
One way in which TLR9 function can be improved was
discovered based on an analysis of the human inhibitory
NK cell receptor KIR3DL2 (p140), which was known to be
specific for a small group of HLA-A alleles. This cell
surface receptor directly binds CpG DNA and delivers it to
endosomes, which improves cytokine production by NK
cells in response to microbial DNA [31]. Therefore, in
addition to MHC-I binding, members of structurally dis-
tinct human and mouse receptor families are also involved
in TLR signaling. It will be interesting to see whether
recognition of MHC-I and of CpG DNA are separate
functions, or whether MHC-I and CpG recognition is
instead coordinated. If so, the physiological function of
MHC-I recognition in this innate immune response to
microbes remains to be defined.
Subsequent to C-type lectin-like Ly49 receptors and
KIR, immunoglobulin-like human LILRB1 and LILRB2
receptors and the homologous mouse PIR-B receptor were
identified as a third type of inhibitory MHC-I receptor that
is relatively broadly expressed by lymphoid, as well as
myeloid, cells. Further, these receptors bind a wide range
of classical and non-classical MHC-I molecules with low
affinity and with limited allele specificity (reviewed in
[32]). LILRB1 (ILT2) inhibits NK cell effector function in
response to target cells expressing MHC-I [33], and
LILRB/PIR receptors generally dampen the stimulation of
immune responses upon binding to MHC-I molecules on
antigen-presenting cells [33]. Subsequently, LILRB/PIR-B
receptors were found to associate with MHC-I molecules in
cis [14, 28]. This extended ligand binding in cis by C-type
lectin-like receptors to structurally unrelated Ig-like
receptors suggested that cis binding of MHC-I impacts
numerous hematopoietic cell types and is not restricted to
NK cells.
Similarly to Ly49, the association between MHC-I and
LILRB/PIR-B receptors in cis is constitutive [14]. How-
ever, in contrast to Ly49, the ITIMs of LILRB/PIR-B
receptors are constitutively phosphorylated and cis asso-
ciation results in constitutive inhibition signaling [14]. In
mast cells, the suppressive effect increases the threshold for
degranulation upon activation through the Fc receptor for
IgE, FceRI [14]. The interaction of LILRB2/PIR-B with
MHC-I in cis reduces activation signaling and maturation
in additional cell types. The expression of a specific HLA-B
allele (HLA-B35x), for which LILRB2 has increased
affinity, is associated with impaired maturation and cyto-
kine production by dendritic cells (DC). It has been
proposed that recognition of the DC’s own HLA-B35x by
LILRB2 contributes to this impairment and that this cor-
relates with accelerated disease in HIV patients who carry
the HLA-B35x allele [34]. Further, the activation of T cells
by DCs is reduced due to competition between the CD8 co-
receptor (on the T cell) and PIR-B (on the DC) for binding
to MHC-I on the DC [35]. Collectively, therefore, cis
association of LILRB/PIR-B receptors with MHC-I medi-
ates a suppressive effect, which is further increased upon
engagement of MHC-I in trans. Even though it is not
known whether cis association of LILRB/PIR-B receptors
is stable, it results in an increased threshold for cellular
activation, similar to the role of cis binding by CD22. For
LILRB/PIR-B receptors, it is not clear how the cis complex
couples to the various activation receptors. In contrast, cis
binding by Ly49 receptors mainly serves as a competitive
inhibitor for trans binding, which lowers the activation
threshold in NK cells. Together, these findings suggest that
cis binding of MHC-I molecules can play distinct biolog-
ical roles.
NK cell education
In addition to dampening the effector function of NK cells
during target cell recognition, inhibitory receptors specific
for MHC-I impact NK cell function in another way.
Engagement of MHC-I, possibly during development,
improves the function of activating NK cell receptors [26,
36–39]. This effect is known as NK cell ‘‘education’’ [40].
The improved functionality of activation receptors may be
essential for NK cell reactions to cells lacking MHC-I in
the absence of acute inflammation. While it is clear that
engagement of MHC-I receptors induces functional chan-
ges, it is currently not possible to identify educated NK
cells based on phenotypic changes. In addition, the precise
role of inhibitory receptors for NK cell education is
debated. The ‘‘licensing’’ model implies that NK cell
activation receptors are by default hypo-active. They are
rendered responsive when NK cells express an inhibitory
receptor specific for self-MHC-I [26, 38]. Conversely, the
‘‘disarming’’ model [41] implies that activating NK cell
receptors are by default active. They are rendered hypo-
active due to continuous stimulation. This is prevented by
the acquisition of an inhibitory receptor, which is specific
for self-MHC [37]. Irrespective of the precise mechanism
involved, both models imply that NK cell education
depends on an interaction of inhibitory receptors with
MHC-I expressed on other cells. However, the fact that
most inhibitory Ly49 NK cell receptors also bind MHC-I
on the NK cell itself raised the issue of whether NK cell
education depends on MHC-I recognition in trans or in cis.
This question was addressed using a Ly49 receptor variant,
which binds MHC-I in trans, but fails to bind in cis. This
was achieved by replacing the predicted flexible stalk
region of Ly49A with a rigid stalk from another C-type
lectin-like receptor, CD72, which should prevent cis
binding by directing the ligand-binding domains of Ly49A
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away from the NK cell membrane. Indeed, this receptor
variant failed to bind MHC-I in cis while retaining the
ability to inhibit NK cell effector function in response to
target cells expressing H-2Dd. Despite the fact that this
engineered receptor was a functional inhibitory NK cell
receptor, it was unable to educate NK cells [42]. These data
dissociate the classical inhibitory from the educating
function of an MHC-I receptor. Such dissociation is not
compatible with ‘‘disarming’’, as this model relies exclu-
sively on the inhibitory function of MHC-I receptors. In
addition, the data suggest that cis interaction is necessary
for NK cell education. In agreement with this conclusion,
an increasing affinity of wild type Ly49A for MHC-I
enhances NK cell education, and, as discussed above, this
correlates with the extent to which Ly49A is associated
with MHC-I in cis [25].
A key question, then, is how cis interaction contributes
to NK cell education. Once again, sequestration of Ly49
by MHC-I expression in cis seems to play a role. We
noted that unengaged Ly49 receptors (i.e.. Ly49 receptors,
which have no MHC-I ligand in a particular mouse strain,
such as Ly49A in H-2b mice), dampen NK cell activation.
In this situation, unengaged Ly49 receptors may be in
proximity to activation receptors, thereby reducing their
responsiveness. As a precedent, the proximity of the co-
inhibitory CD22 receptor is sufficient to dampen BCR
stimulation, despite the fact that CD22 is not engaged by
a trans ligand. In agreement with this model, the sup-
pressive effect of unengaged Ly49A requires a functional
cytoplasmic inhibition motif [43]. Finally, unengaged
Ly49A, as well as KIR [43], accumulate at NK cell
synapses formed with target cells, which lack the corre-
sponding MHC-I ligand [42]. The presence of MHC-I
ligand in cis is believed to sequester Ly49A away from
activation receptors, which reverses the suppressive effect
of unengaged Ly49A and improves the function of NK
cell activation receptors.
As discussed above, NK cell education by Ly49A is
dependent on cis interaction with MHC-I. This raises the
question of how receptors, which do not bind MHC-I in cis
(such as KIR2DL1 or CD94/NKG2A), are able to educate
NK cells. One structural difference between these receptors
is that KIR2DL1 and CD94/NKG2A contain two immu-
noreceptor tyrosine-based inhibition motifs (ITIMs) in their
cytoplasmic domains. By contrast, each subunit of the
homodimeric Ly49 receptors has a single ITIM. Perhaps
the tandem arrangement of ITIMs can lead to distinct types
of signals based on ligand binding in trans. Consistent with
such a possibility, KIR2DL1 can play a costimulatory or an
inhibitory role in CD4? T cell hybridomas [44]. For Ly49
receptors, their sequestration by MHC-I expression in cis,
rather than signaling induced by cis binding, appears to be
essential for NK cell education.
Irrespective of the precise mechanism, cis association of
ITIM-bearing Ly49 receptors improves the function of
mouse NK cells in two separate ways: it improves the
function of activating NK cell receptors and it reduces the
inhibitory capacity of MHC-I receptors. Both effects con-
tribute to lowering the threshold at which NK cell
activation will exceed inhibition signals, rendering NK
cells more reactive and potentially more useful.
Cis binding by activating receptors
Cis binding was initially observed for inhibitory Ly49 and
LILRB receptors, while an activating Ly49 family receptor
was not influenced by the presence of its ligand in cis [45],
raising the question of whether cis interaction is restricted
to cell surface receptors with inhibitory function. However,
this is not the case, as evidence for cis–trans binding has
now been reported for activating receptors that recognize
non-MHC ligands. A recent example includes the TNF
family receptor herpes virus entry mediator (HVEM),
which is subject to regulation by its ligand, B and T lym-
phocyte attenuator (BTLA), present on the T cell
membrane. HVEM engagement of BTLA expressed on
neighboring cells results in bi-directional signaling: the
HVEM-expressing cell is strongly co-stimulated while
the BTLA-expressing cell is co-inhibited. This raised the
question of how naı¨ve HVEM-expressing T cells are kept
in check. Recent data show that HVEM is constitutively
associated with BTLA in cis and acts as a competitive
inhibitor, which prevents HVEM clustering by ligand
engagement in trans [16]. Consequently, HVEM–BTLA
cis complexes are thought to maintain T cells in a naı¨ve
state. Upon T cell activation, BTLA is downregulated,
which renders HVEM competent for signaling. These
findings suggest that cis association makes the activating
HVEM receptor functionally unavailable, whereas trans
binding results in signaling. Similar to Ly49, cis binding of
HVEM serves as a competitive inhibitor for trans binding.
Activating receptors that can bind the equivalent ligand
expressed in cis and trans are not restricted to the immune
system. Ephrin receptors (Eph) are involved in the sorting
of distinct cell types in various tissues, such as the gut, or in
directing the growth of axons. Cell sorting occurs based on
cellular repulsion, which is induced when Eph binds ephrin
ligands on other cells. Recent data suggest that the activity
of certain Eph is influenced by ephrin expression by the
same cell [46]. For example, the EphA receptor binds
ephrinA ligand expressed in cis via the Eph ligand-binding
domain [13]. Similar to HVEM, cis interaction does not
induce Eph tyrosine kinase activity; rather, it reduces the
interaction with ephrin on other cells, which dampens the
repulsive signaling by Eph [13]. In a functionally related
system, plexin receptors on neurons bind to semaphorin
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ligands on other cells (trans interaction) and transduce
signals for regulating neuronal axon guidance. However,
expression of Plexin-A4 and Semaphorin6A on the same
neuron was found to attenuate the response to semaphorin
ligands in trans [17]. This effect is mediated by the for-
mation of stable complexes between Plexin-A4 and
Semaphorin6A in cis, which prevent ligand binding in
trans. In this way, the Plexin-A4–Semaphorin6A cis
interaction serves as an inhibitory mechanism to modulate
axon guidance.
Finally, recent data suggest that the activity of the Notch
receptor is influenced by cis binding to its Delta ligand
[15]. Notch induces distinct cell fates in groups of initially
identical cells, a process referred to as lateral signaling.
Delta has two activities: it activates Notch in neighboring
cells and it inhibits Notch expressed on the same cell. The
negative effect is based on the interaction of the two pro-
teins in cis, which prevents trans binding by the receptor.
Functional data demonstrate that the response of Notch to
Delta expressed in trans is graded (i.e., it is proportional to
the amount of Delta present on a neighboring cell). Delta
expression in cis serves as a competitive inhibitor for
Notch activation by trans Delta. Mathematical modeling
and functional data showed that this generates a very sharp
threshold, above which Notch responds to trans Delta [47].
This Notch–Delta switch may explain how very small
differences in the relative concentrations of Notch and
Delta on the surfaces of two cells can be translated into
binary cell fates.
Altogether, there is now ample evidence from multiple
distinct receptor–ligand systems that the ability of a cell
surface receptor to respond to ligand on a neighboring cell
may be subject to control by expression of the same ligand
on the same cell. In most of these cases, cis binding does
not induce receptor signaling. Rather, by competitively
inhibiting trans binding, cis interaction modifies the
threshold at which the cell will be activated.
Cis binding and viral infection
HVEM was originally identified as the receptor for herpes
simplex virus envelope glycoprotein D (HSV gD) [48].
Based on the formation of a cis complex between HVEM
and BTLA, the viral envelope protein gD was also tested
for association with HVEM in cis. This was indeed the
case; however, the functional consequence of this interac-
tion was different from the HVEM–BTLA cis association.
Whereas the HVEM–BTLA complex is functionally inert,
the HVEM–gD cis complex activates NF-jB signaling
[16]. NF-jB activation induces the expression of pro-sur-
vival genes and may provide infected cells with a selective
survival advantage early during HSV infection. These data
suggest that certain viruses exploit the ability of cell
surface receptors to bind ligand in cis in order to generate
cell-autonomous signals that favor infected cells.
Perhaps along the same lines, in addition to binding
HLA molecules, LILRB1 recognizes the HLA-like mole-
cule UL18 encoded by human cytomegalovirus (HCMV)
[49]. The fact that LILRB1 binds MHC-I in cis raises the
issue of whether UL18 might also interact with LILRB1 on
the surface of HCMV-infected cells and, if so, whether this
has functional consequences similar to or distinct from
MHC-I binding in cis.
Structural basis for cis versus trans interaction
From a structural perspective, it is not obvious how a cell
surface receptor can bind a ligand in both cis and trans
using the identical binding site. In addition, it is not known
why cis and trans binding results in distinct functional
outcomes. These issues have been addressed for the inter-
action of Ly49 receptors with MHC-I ligand [50]. These
studies revealed that Ly49 receptors adopt two distinct
conformations to mediate cis–trans recognition.
Ly49 receptors are homodimeric type II glycoproteins,
with each chain composed of a ligand-binding C-type
lectin-like domain, the so-called natural killer receptor
domain (NKD), which is connected by an unusually long
stalk of around 70 residues to the transmembrane and
cytoplasmic domains [51, 52]. Based on the crystal struc-
ture of Ly49L, which was the first to provide structural
information regarding the stalk region, we proposed that
the NKDs must back-fold onto a specific segment of the
stalk region, the so-called aS3 segment, to bind MHC-I in
trans (Fig. 2a). In agreement with this model, replacement
of the aS3 segment greatly reduces the ability of the Ly49A
receptor to functionally engage MHC-I on other cells [50],
validating the proposal that Ly49 trans binding is mediated
by an unusual receptor conformation in which the NKDs
are back-folded onto the stalk.
The crystal structure of Ly49L without the stalk region
revealed distinct non-covalent associations of the two
NKDs in the absence as compared to the presence of the
stalk. These data, together with the earlier co-crystal
structure of Ly49A bound to H-2Dd [19], raised the pos-
sibility that Ly49 receptors assume an extended
conformation, in which the aS3 segments of the stalk do not
contact the NKDs, to bind MHC-I in cis (Fig. 2b). Indeed,
the aS3 segment, which is essential for functional trans
binding, is not required for cis binding, providing evidence
that the NKDs are disengaged from the stalk during cis
interactions. In addition, progressive shortening of the stalk
region impaired trans rather than cis binding. This is
expected if cis binding is mediated by an extended receptor
conformation. Based on the model (Fig. 2), it is easy to
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envisage how cis binding by a receptor with a shortened
stalk can be accommodated, while trans binding is
impaired by structural clashes between the MHC-I mole-
cules and the NK cell membrane. Finally, biochemical
analyses confirmed that the cis complexes consist of an
Ly49A homodimer associated with a single Dd molecule,
as predicted by the model (Fig. 2b). By contrast, trans
complexes consist of an Ly49A homodimer associated with
two Dd molecules (Fig. 2a) [50].
Cis and trans interactions of Ly49 NK cell receptors
with MHC-I are thus mediated by two distinct receptor
conformations. The two ligand-binding domains of Ly49
are back-folded onto the long stalk region to bind two
MHC-I molecules in trans. Dissociation of the ligand-
binding domains from the stalk and their reorientation
relative to the NK cell membrane allow monovalent
binding of MHC-I in cis. The back-folded and extended
configurations define the structural basis for cis–trans
binding by Ly49 receptors (schematically shown in
Fig. 1a).
Cis–trans binding may generally depend on large
structural rearrangements that allow cell surface receptors
to inverse the orientation of the ligand-binding domain
relative to the cell membrane. While cis–trans binding of
Ly49 receptors depends on an unusually long stalk ([70
amino acids), the stalk regions of LILRB/PIR-B receptors
are considerably shorter (42–52 amino acids). In addition,
these receptors are composed of four or six extracellular
Ig-like domains [33, 49], whereby the membrane distal D1
and D2 domains mediate MHC-I binding. Based on the
corresponding specificity of trans and cis binding [14], it
seems likely that LILRB/PIR-B receptors use the same
binding site for the two types of interactions. If that is
indeed the case, the D1 and D2 domains of LILRB1 must
reverse direction with respect to the effector cell surface to
bind MHC-I in cis. This would require that the receptor
bends back on itself to adopt a horseshoe-shaped configu-
ration of the four Ig domains, implying considerable
flexibility in the segment connecting the D2 and D3
domains. As a precedent, the four N-terminal Ig-like
domains of the Drosophila Dscam protein do assume a
horseshoe arrangement, which depends on a very short,
five-residue hinge between D2 and D3 [53]. In the case of
PIB-B, which has six Ig-like domains, the segments con-
necting D4–D5 or D5–D6 may provide additional
flexibility. Therefore, the ability to reverse the orientation
of their ligand-binding domains may be a general feature of
receptors that bind in cis and trans (schematically shown in
Fig. 1b). Such reversals may be made possible by two
distinct structural features: long stalk regions in the case of
Ly49s and flexible interdomain hinges in the case of
LILRB2 and PIR-B.
Recent data point to an additional structural solution for
cis binding. As discussed above, Notch interacts with Delta
in cis and trans. However, the extracellular domains of
Notch and Delta are composed of EGF-like domains that
are thought to form extended and rigid structures. Not-
withstanding, structural and functional analyses suggest
Fig. 2 Trans and cis interactions of Ly49 receptors with MHC-I
ligands. a Trans interaction of an Ly49 receptor with two MHC-I
molecules. The MHC-I heavy chain is cyan; b2m is green; the Ly49
NKD is red; the a3S helix of the Ly49 stalk and loop LS connecting
a3S to the NKD are blue; the disulfide bond linking the a3S helices is
magenta. The predicted a1S and a2S helices of the stalk are drawn
arbitrarily in orange and yellow, respectively, with the putative
disulfide bond in magenta. The ligand-binding domains in the Ly49
homodimer are back-folded onto the stalk to bind two MHC-I
molecules on a target cell. b Cis interaction of Ly49 with a single
MHC-I molecule. The Ly49 receptor assumes an extended confor-
mation, which engages a single MHC-I molecule on the NK cell
itself. The ligand-binding domains are thereby dissociated from the
stalk region. Reproduced with permission from Immunity [50]
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that Notch–ligand interactions use the same surfaces for cis
and trans binding. In silico docking of crystal structures of
the binding domains of Notch with that of its ligand, Jag-
ged, provided evidence for two distinct receptor–ligand
complexes [15]. An anti-parallel engagement of receptor
and ligand is thought to mediate a trans interaction.
Unexpectedly, there is also the possibility of a parallel
engagement that would allow cis binding. Anti-parallel and
parallel binding modes appear to be possible because the
respective binding sites are symmetric. Even though this
model remains to be further tested, symmetry of binding
sites does represent, in principle, an additional solution to
the structural problem of how cell surface receptors can
bind the same ligand in cis and trans (schematically shown
in Fig. 1c).
Basis for the divergent outcomes of cis and trans
binding
An important unresolved issue is how cis and trans binding
can result in distinct functional outcomes. Receptor
engagement in trans is normally productive and results in
receptor signaling. In contrast, binding of the same ligand in
cis, using the same binding site, is often non-productive. The
engagement of cell surface receptors induces intracellular
signaling via two principal mechanisms: ligand-induced
structural changes in the receptor and/or oligomerization of
receptor–ligand complexes [54]. For Ly49 receptors, it was
shown that Ly49C in complex with H-2Kb retains nearly the
same structure as the free receptor [55], arguing against
MHC-induced conformational changes in Ly49 as a sig-
naling mechanism. On the other hand, monovalent human
KIR-HLA-C complexes are thought to multimerize in a
zinc-dependent fashion, and this seems to be needed for
inhibitory signaling at the NK cell immune synapse [56].
Similarly, Ly49 signaling may depend on clustering of
ligand-engaged Ly49 dimers. Although a single Ly49
receptor can associate with two MHC-I molecules to form a
bivalent Ly49–MHC-I complex (Fig. 2a), it is not apparent
how higher-order clustering of Ly49–MHC-I complexes
might assemble. A prominent feature of the Ly49L struc-
ture, which contains a portion of the stalk region, is a flexible
loop region that connects the a3S segment with the NKD.
This so-called LS loop is not needed for MHC-I binding in
trans. Surprisingly, however, LS is essential for the inhibi-
tory function of the Ly49A receptor and is required for
receptor accumulation at the immune synapse. In the model
of the bivalent Ly49–MHC-I trans complex (Fig. 2a), the LS
loop is on the exterior of the complex, fully exposed to
solvent. It is thus conceivable that LS mediates lateral
interactions with other cell surface molecules or adjacent
bivalent Ly49–MHC-I trans complexes, and that these
lateral associations are required for receptor signaling.
Importantly, in the cis complex, where the NKDs are dis-
sociated from the stalk, the Ls loop must adopt an extended
conformation (Fig. 2b). This structural change may prevent
LS from mediating lateral association of Ly49 receptors that
are bound to MHC-I in cis. Accordingly, in situations where
cis complexes are inert, cis engagement may be mediated by
receptor conformations that cannot cluster.
Concluding remarks
A significant number of cell surface receptors have now
been shown to be able to interact with ligands in both cis
and trans. Two general scenarios emerge from these dif-
ferent receptor–ligand systems with regard to the role of cis
interaction: First, the binding of a ligand to its receptor in
cis is functionally inert and serves as a competitive inhib-
itor for receptor binding in trans. Second, the binding of a
ligand to its receptor in cis results in tonic (inhibition)
signaling, which is enhanced when the receptor is engaged
in trans. In both cases, cis binding alters the threshold at
which cells produce a response to an external stimulus. Cis
binding may be stable to permanently modify the threshold
for a response. Alternatively, cis and/or trans ligands may
be subject to regulation or trans ligand may compete with
cis ligand for receptor binding. In these cases, the threshold
response may vary depending on the relative abundance of
cis and trans ligand. Consequently, the various flavors of
cis binding may allow for diverse ways in which receptor
function is not only dependent on the presence of ligand on
other cells but can also be modified by the presence of
ligand on the same cell.
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